Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of a Novel Model Based on Plasma cfDNA Assay and MRl Lmaging in the Detection of Prostate Cancer

NCT06509919 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT06509919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06509919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of a Novel Model Based on Plasma cfDNA Assay and MRl Lmaging in the Detection of Prostate Cancer
Lead sponsor
Shanghai Changzheng Hospital
Phase
Observational
Overall status
Suspended
Start date
July 9, 2024
Completion date
December 31, 2026
Enrollment
1,600 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer